Immunotherapy of Atopic Dermatitis by Injections of Antigen-Antibody Complexes

Atopic dermatitis (AD) is a pruriginous inflammatory skin disease characterized by a clinical and histological aspect of eczema, a typical topography and a chronic fluctuating evolution. Its frequency has been estimated to be as high as 10% in children and 1-2% in adults [1]. Although the precise etiology of AD is not entirely understood, a number of arguments indicate its immune nature. The key role played by Langerhans’ cells and cytokines is presently better understood [2]. On the other hand, hyperreactivity towards allergens of the environment seems to play a primary role, an assumption based on both biological [3] and clinical grounds [4]. Among those allergens, Dermatophagoides pteronyssinus, one of the main house dust mites, plays a determining role in symptom triggering and exacerbation, due to its ubiquitous nature and presence in the environment all over the year [5].

Considering the importance of AD and the lack of specific therapy, we have studied the potential benefit of immunotherapy using antigen-antibody complexes made from D. pteronyssinus allergens and specific autologous antibodies. The rationale behind this research was based on the fact that such complexes could, under some experimental circumstances, specifically suppress the immune response towards allergens contained in the complexes [6].

A previous experience in allergic bronchial asthma had shown a highly significant improvement associated with reduction in both specific IgE and IgG antibodies [7]. A first study carried out as an open trial with AD patients, i.e. 10 patients selected according to clinical criteria of severity and chronicity, had shown encouraging results [8]. The solution of antigen-antibody complexes used for injections was obtained by preparing specific antibodies from each of the patient’s serum, a procedure which necessitated a number of steps which are described in the corresponding...
publication. The results obtained in that study could not be attributed to the spontaneous
evolution of disease, even though the trial was not controlled. The treatment was pursued over 3
years in 8 patients, 5 of whom had practically no residual skin lesions after 2 years of follow-up,
while the 3 others had a partial recurrence. An average improvement of more than 80% was
observed in those 8 patients [9].
A double-blind placebo-controlled study was thus performed with 24 adult patients with severe
AD, which has confirmed both the efficacy and safety of this novel therapy [10]. However, the
very fact that the procedure has to be carried out with autologous antibodies, and therefore
requires a long and cumbersome preparation procedure, somewhat limits its usefulness on a
larger scale. Alternative methods are currently under evaluation to simplify procedures of
antibody purification and to allow an easier and wider application.

© 1993 S. KargerAG. Basel 1018-8665/93/1864-0276
$ 2.75/0
References
Shultz-Larsen F, Holm NV, Henningsen K: Atopic dermatitis: A genetic-epidemiologic study in
Bieber T, Bruijnzeel-Koomen C: La cellule de Langerhans dans la physiopathologie de la der-
Mudde GC. van Reijsen FC. Boland GC, de Gast GC, Bruijnzeel PLB, Bruijnzeel-Koomen
CAF M: Allergen presentation by epidermal Langerhans’ cells from patients with atopic
dermatitis is mediated by IgE. Immunology 1990;69:335-341.
Clark R. Adinoff A: Aeroallergen contact can exacerbate atopic dermatitis: Patch tests as a
1979;281:488-490.
Machiels JJ. Somville MA. Lebrun PM, Le-becque SJ. Jacquemin MG, Saint-Remy , JMR:
Allergic bronchial asthma due to D. pteronyssinus hypersensitivity can be efficiently treated by
Leroy B. Lachapelle JM. Somville MM, Jacquemin MG. Saint-Remy JMR: Injection of allergen-
antibody complexes is an effective treatment of atopic dermatitis. Dermatologica 1991;182:98-
106.
Leroy BP, Lachapelle JM. Jacquemin MG. Saint-Remy JMR: Treatment of atopic dermatitis by
allergen-antibody complexes: Long-term clinical results and evolution of IgE antibodies.
Am Acad Dermatol, in press.
277